Cisplatin is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Alvogen Inc.. The primary component is Cisplatin.
| Product ID | 47781-610_4f1e86f3-8144-a1e9-6f03-cab6bebd2e13 |
| NDC | 47781-610 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Cisplatin |
| Generic Name | Cisplatin |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2017-09-25 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA207323 |
| Labeler Name | Alvogen Inc. |
| Substance Name | CISPLATIN |
| Active Ingredient Strength | 100 mg/100mL |
| Pharm Classes | Platinum-based Drug [EPC],Platinum-containing Compounds [EXT] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2017-09-25 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | ANDA |
| Application Number | ANDA207323 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2017-09-25 |
| Marketing End Date | 2020-03-01 |
| Ingredient | Strength |
|---|---|
| CISPLATIN | 100 mg/100mL |
| SPL SET ID: | 61fc9585-d1db-6c41-eb05-8c96d811b2ec |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0143-9504 | CISplatin | Cisplatin |
| 0143-9505 | CISplatin | Cisplatin |
| 0703-5747 | Cisplatin | Cisplatin |
| 0703-5748 | Cisplatin | Cisplatin |
| 16729-288 | Cisplatin | Cisplatin |
| 44567-509 | CISplatin | CISplatin |
| 44567-510 | CISplatin | CISplatin |
| 44567-511 | CISplatin | CISplatin |
| 44567-530 | Cisplatin | cisplatin |
| 47781-609 | Cisplatin | cisplatin |
| 47781-610 | Cisplatin | cisplatin |
| 63323-103 | Cisplatin | CISPLATIN |
| 68001-283 | Cisplatin | Cisplatin |
| 68083-162 | CISPLATIN | Cisplatin |
| 68083-163 | CISPLATIN | Cisplatin |
| 70860-206 | Cisplatin | cisplatin |
| 61126-003 | Platinol | cisplatin |
| 61126-004 | Platinol-AQ | cisplatin |